Why Hims & Hers Stock Dropped Today
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Hims & Hers to offer at-home blood draws and lab testing with new acquisition
Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.
Hims & Hers stock surges 23%: Telehealth company announces expansion into blood testing weeks after Super Bowl buzz
Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Market Whales and Their Recent Bets on HIMS Options
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...
Business Wire1d
Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers
Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab ...
Hims & Hers: The Pros And Cons Of The Trybe Acquisition
Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...
Money Morning1d
Is Hims & Hers In the Midst of a Short Squeeze?
What Hims & Hers stock could be witnessing now is a short-squeeze. As its stock began rising sharply, short-sellers move to get out. So over the past week, we’ve seen shares surge 60%. In midday ...
Hims & Hers price target raised to $21 from $18 at BofA
BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...